Mecamylamine is also sometimes used as an antiaddictive drug to help people stop smoking tobacco,[7] and is now more widely used for this application than it is for lowering blood pressure.

[medical citation needed] In a recent double-blind, placebo-controlled Phase II trial in Indian patients with major depression, (S)-mecamylamine (TC-5214) appeared to have efficacy as an augmentation therapy.

This is the first substantive evidence that shows that compounds where the primary pharmacology is antagonism to neuronal nicotinic receptors will have antidepressant properties.

[12] It did not produce meaningful, beneficial results on patients as measured by changes on the Montgomery-Asberg Depression Rating Scale after eight weeks of treatment as compared with placebo.

[16] Another, more recent SAR study was undertaken by Suchocki et al.[17] A comprehensive review of the pharmacology of mecamylamine was published in 2001.